Assess whether biosimilarity is analytically justified (60029c)

Situation

The desk packet is 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal. RWE evidence-strategy director in a company with a CMC site change mid-review has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy file.

Decision

RWE evidence-strategy director in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• Authorize Proceed under protocol now; 505(b)(2) literature-to-product bridge table already has the discriminator after a DSMB note on an imbalance that is not yet a signal.
• Keep Pause the pathway in force until 505(b)(2) literature-to-product bridge table is completed after a DSMB note on an imbalance that is not yet a signal for RWE evidence-strategy director.
• Treat 505(b)(2) literature-to-product bridge table as Escalate safety review because both readings appear after a DSMB note on an imbalance that is not yet a signal.
• Refuse a Pharma & Life Sciences close: RWE evidence-strategy director does not have the page biosimilarity is analytically justified turns on in 505(b)(2) literature-to-product bridge table.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim RWE evidence-strategy director would keep.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move biosimilarity is analytically justified for RWE evidence-strategy director.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal). The follow-on Clinical and Evidence Strategy action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.